Abstract

IntroductionIdiopathic Pulmonary Fibrosis (IPF) is a progressive, incurable fibrotic interstitial lung disease with a prognosis worse than many cancers. Its pathogenesis is poorly understood. Activated platelets can release pro-fibrotic mediators that have the potential to contribute to lung fibrosis. We determine platelet reactivity in subjects with IPF compared to age-matched controls.MethodsWhole blood flow cytometry was used to measure platelet-monocyte aggregate formation, platelet P-selectin expression and platelet fibrinogen binding at basal levels and following stimulation with platelet agonists. A plasma swap approach was used to assess the effect of IPF plasma on control platelets.ResultsSubjects with IPF showed greater platelet reactivity than controls. Platelet P-selectin expression was significantly greater in IPF patients than controls following stimulation with 0.1 µM ADP (1.9% positive ±0.5 (mean ± SEM) versus 0.7%±0.1; p = 0.03), 1 µM ADP (9.8%±1.3 versus 3.3%±0.8; p<0.01) and 10 µM ADP (41.3%±4.2 versus 22.5%±2.6; p<0.01). Platelet fibrinogen binding was also increased, and platelet activation resulted in increased platelet-monocyte aggregate formation in IPF patients. Re-suspension of control platelets in plasma taken from subjects with IPF resulted in increased platelet activation compared to control plasma.ConclusionsIPF patients exhibit increased platelet reactivity compared with controls. This hyperactivity may result from the plasma environment since control platelets exhibit increased activation when exposed to IPF plasma.

Highlights

  • Idiopathic Pulmonary Fibrosis (IPF) is a progressive, incurable fibrotic interstitial lung disease with a prognosis worse than many cancers

  • Platelet P-selectin expression was significantly greater in IPF patients than controls following stimulation with 0.1 mM adenosine diphosphate (ADP) (1.9% positive 60.5 versus 0.7%60.1; p = 0.03), 1 mM ADP (9.8%61.3 versus 3.3%60.8; p,0.01) and 10 mM ADP (41.3%64.2 versus 22.5%62.6; p, 0.01)

  • Platelet fibrinogen binding was increased, and platelet activation resulted in increased platelet-monocyte aggregate formation in IPF patients

Read more

Summary

Introduction

Idiopathic Pulmonary Fibrosis (IPF) is a progressive, incurable fibrotic interstitial lung disease with a prognosis worse than many cancers. Idiopathic pulmonary fibrosis (IPF) is the most common fibrotic interstitial lung disease and has a prognosis worse than many cancers [1]. Therapies targeting the coagulation cascade have been investigated in IPF, but a large randomised controlled trial of the vitamin K antagonist warfarin was stopped early because of increased mortality associated with the intervention [7]. This demonstrates that selectively targeting the coagulation system is ineffective and potentially harmful in IPF and suggests an alternative pathway may be responsible for the observed link between fibrosis and vascular disease

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call